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Abstract This biographical sketch on John Albert Key
corresponds to the historic text, The Classic: Sulfonamides
in the Treatment of Chronic Osteomyelitis, available at
DOI 10.1007/s11999-009-0797-7.
John Albert Key was born in 1890. I have been unable to
learn of his early life, but he graduated from the Alabama
Technical Institute in 1913 [5] and subsequently from
Johns Hopkins Medical School in 1918 [1, 2]. Hopkins,
like so many other institutions, organized a hospital unit for
the war effort and Key, along with 32 other students,
volunteered for that effort in 1917. During the winter of
1917–1918 he worked in the unit as a private under Dr. Joel
Goldthwait in Bazoilles-sur-Meuse, France. In the spring of
1918 he received word he had been awarded the MD
degree. After returning to the States in 1919 he received
his postgraduate training at Children’s Hospital and the
Massachusetts General Hospital in Boston. On completion
of his training in 1922 he moved to the University of
Maryland as an instructor in orthopaedic surgery. He then
moved to Washington University in St. Louis as an asso-
ciate in clinical orthopaedics in 1926, became chair in
1931, and remained affiliated with that institution until his
death in 1955.
Albert Key was active in many aspects of orthopaedic
organizations, having apparently never missed a meeting of
the American Orthopaedic Association [5] and serving as
its president in 1945–6. However, the list of organizations
in which he served is indeed long, He was also a prolific
contributor to the literature in areas as diverse as tumors,
trauma, infection, spine, degenerative and inflammatory
conditions, including many experimental studies in ani-
mals, and had a commanding knowledge of those fields.
The article we highlight this month relates to the use of
sulfonamides in osteomyelitis [3]. Various forms of sulfa
drugs were introduced in the 1930s [6]. Interestingly, the
first drug, Prontosil (Bayer Laboratories, Frankfurt,
Germany), had no effect in the test tube, and a French
team at the Pasteur Institute discovered in vivo the drug
was metabolized into two portions, only one of which,
sulfanilamide, was active. Hundreds of manufacturers
subsequently produced various forms, one of which con-
tained diethylene glycol, poisoning hundreds of people,
and contributing to the enactment of the Federal Food,
Drug, and Cosmetic Act in 1938. Key was one of the early
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investigators of sulfa drugs for musculoskeletal infections
[4], performing both experimental and clinical studies, and
suggesting they might impair wound healing. In the article
we reproduce here [3], Key noted:
‘‘…sulfonamides in the blood stream cannot exert
their maximum effects upon bacteria in localized
areas of disease…’’ but ‘‘…the systemic administra-
tion of sulfadiazine, and especially sulfathiazole, to
patients with acute osteomyelitis or an acute exacer-
bation of chronic osteomyelitis, usually has a
beneficial effect, not only upon the septicaemia, but
also upon the local disease.’’
Key emphasized the drugs were only an adjunct to
appropriate surgery, and that local application was also
helpful. He was careful to note the dangers of the drug,
including local reactions to too much added sulfa. Even
though a proponent of the Orr method of treatment
(de´bridement and casting with repeat treatments as neces-
sary, and leaving the wound to close by secondary
intention), Key recognized sulfa drugs would allow the
primary closing of many wounds and avoidance of a
‘‘…longer interval (of treatment) and considerable
unpleasantness.’’ Dr. Key was a careful researcher, always
cognizant of the potential downsides of treatment, but
eager to explore new methods with proper experimental
studies.
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